Product Overview
CJC‑1295 – Research‑Grade GHRH Analogue for Endocrine and Growth‑Axis Pathway Investigation
Synonyms: Modified GRF (1‑29); CJC‑1295 with DAC (if specified); GHRH(1‑29) analogue
CAS Number: 863288‑34‑0 (CJC‑1295 with DAC)
Sequence: Tyr‑Ala‑Asp‑Ala‑Ile‑Phe‑Thr‑Asn‑Ser‑Tyr‑Arg‑Lys‑Val‑Leu‑Gly‑Gln‑Leu‑Ser‑Ala‑Arg‑Lys‑Leu‑Leu‑Gln‑Asp‑Ile‑Met‑Ser‑NH₂ (Modified GRF 1‑29)
Molecular Weight: Approx. 3,364 Da (non‑DAC) / ~4,900+ Da (DAC‑conjugated)
Form: Lyophilised powder
Purity: ≥98% (HPLC)
Use: For laboratory research only. Not for human or veterinary use.
Overview
CJC‑1295 is a synthetic analogue of growth hormone‑releasing hormone (GHRH), engineered to investigate endocrine signalling, growth hormone axis regulation, and peptide–receptor interactions in controlled laboratory models.
Two primary research forms exist: CJC‑1295 with DAC (Drug Affinity Complex) and Modified GRF (1‑29), the shorter non‑DAC variant.
Both are widely used in studies examining GHRH‑receptor activation, pulsatile GH secretion, and downstream IGF‑1‑related pathways in non‑human systems.
Mechanistic Insights
Preclinical research has explored CJC‑1295 in relation to several biological processes:
• GHRH Receptor Activation – Studied for its ability to stimulate GHRH‑dependent signalling cascades.
• Growth Hormone Axis Modulation – Investigated for its influence on GH release and IGF‑1‑associated pathways in non‑human models.
• Endocrine Feedback Loops – Examined for its involvement in hypothalamic–pituitary regulation.
• Peptide Stability and Half‑Life – DAC‑conjugated forms are evaluated for extended plasma persistence in research settings.
These findings are based on published scientific literature and do not imply any therapeutic or physiological effects in humans.
Research Context
CJC‑1295 is utilised exclusively within controlled laboratory environments for:
• Studies involving GH/IGF‑1 axis regulation
• Investigations into GHRH receptor pharmacology
• Research on endocrine signalling and peptide–receptor interactions
• Comparative studies between DAC and non‑DAC GHRH analogues
This material is not intended for therapeutic, diagnostic, or clinical use.
Packaging & Storage
• Supplied as a sterile‑filtered, lyophilised peptide
• Store at –20°C, protected from light and moisture
• Reconstitute under sterile laboratory conditions using bacteriostatic water or a suitable research‑grade diluent
• Store reconstituted solutions at 2–8°C and use according to institutional guidelines
Additional solubility and technical documentation are available to qualified research institutions upon request.
Compliance Notice
This product is intended solely for laboratory research purposes.
It is not approved for human or veterinary administration and must not be incorporated into food, cosmetics, pharmaceuticals, or any product intended for biological exposure.
All information provided is for scientific and educational reference only. Researchers are responsible for ensuring compliance with all applicable regulations, institutional policies, and safety standards.
